• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2 突破感染与非突破感染后 Spike 特异性增强,但 Nucleocapsid 特异性 T 细胞反应减弱。

Enhanced Spike-specific, but attenuated Nucleocapsid-specific T cell responses upon SARS-CoV-2 breakthrough versus non-breakthrough infections.

机构信息

Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany.

German Centre for Infection Research (DZIF), Munich, Germany.

出版信息

Front Immunol. 2022 Dec 13;13:1026473. doi: 10.3389/fimmu.2022.1026473. eCollection 2022.

DOI:10.3389/fimmu.2022.1026473
PMID:36582222
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9792977/
Abstract

SARS-CoV-2 vaccine breakthrough infections frequently occurred even before the emergence of Omicron variants. Yet, relatively little is known about the impact of vaccination on SARS-CoV-2-specific T cell and antibody response dynamics upon breakthrough infection. We have therefore studied the dynamics of CD4 and CD8 T cells targeting the vaccine-encoded Spike and the non-encoded Nucleocapsid antigens during breakthrough infections (BTI, n=24) and in unvaccinated control infections (non-BTI, n=30). Subjects with vaccine breakthrough infection had significantly higher CD4 and CD8 T cell responses targeting the vaccine-encoded Spike during the first and third/fourth week after PCR diagnosis compared to non-vaccinated controls, respectively. In contrast, CD4 T cells targeting the non-vaccine encoded Nucleocapsid antigen were of significantly lower magnitude in BTI as compared to non-BTI. Hence, previous vaccination was linked to enhanced T cell responses targeting the vaccine-encoded Spike antigen, while responses against the non-vaccine encoded Nucleocapsid antigen were significantly attenuated.

摘要

SARS-CoV-2 疫苗突破性感染即使在奥密克戎变异株出现之前也经常发生。然而,关于接种疫苗对突破性感染时 SARS-CoV-2 特异性 T 细胞和抗体反应动态的影响,我们知之甚少。因此,我们研究了在突破性感染(BTI,n=24)和未接种疫苗的对照感染(非-BTI,n=30)期间针对疫苗编码的 Spike 和非编码核衣壳抗原的 CD4 和 CD8 T 细胞的动力学。与未接种疫苗的对照组相比,疫苗突破性感染患者在 PCR 诊断后第一周和第三/四周时针对疫苗编码的 Spike 的 CD4 和 CD8 T 细胞反应显著更高。相比之下,与非-BTI 相比,BTI 中针对非疫苗编码核衣壳抗原的 CD4 T 细胞的反应幅度明显较低。因此,先前的疫苗接种与针对疫苗编码 Spike 抗原的增强的 T 细胞反应有关,而针对非疫苗编码核衣壳抗原的反应则明显减弱。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52c6/9792977/9851cbb7760a/fimmu-13-1026473-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52c6/9792977/457ad4b991c2/fimmu-13-1026473-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52c6/9792977/9851cbb7760a/fimmu-13-1026473-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52c6/9792977/457ad4b991c2/fimmu-13-1026473-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52c6/9792977/9851cbb7760a/fimmu-13-1026473-g002.jpg

相似文献

1
Enhanced Spike-specific, but attenuated Nucleocapsid-specific T cell responses upon SARS-CoV-2 breakthrough versus non-breakthrough infections.SARS-CoV-2 突破感染与非突破感染后 Spike 特异性增强,但 Nucleocapsid 特异性 T 细胞反应减弱。
Front Immunol. 2022 Dec 13;13:1026473. doi: 10.3389/fimmu.2022.1026473. eCollection 2022.
2
T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy.HIV 感染者在接受抗逆转录病毒治疗的情况下,对 COVID-19 疫苗和突破性感染的 T 细胞反应。
Viruses. 2024 Apr 24;16(5):661. doi: 10.3390/v16050661.
3
Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study.接种疫苗和利妥昔单抗治疗的类风湿关节炎患者突破性感染后 SARS-CoV-2 免疫动力学:一项前瞻性队列研究。
Front Immunol. 2024 Feb 22;15:1296273. doi: 10.3389/fimmu.2024.1296273. eCollection 2024.
4
Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.奥密克戎变异株疫苗突破性感染诱导针对 SARS-CoV-2 奥密克戎 BA.1 的交叉中和反应优于单独感染。
Int J Mol Sci. 2022 Jul 12;23(14):7675. doi: 10.3390/ijms23147675.
5
Dominant CD8 T Cell Nucleocapsid Targeting in SARS-CoV-2 Infection and Broad Spike Targeting From Vaccination.新冠病毒感染中占主导地位的靶向核衣壳的CD8 T细胞及疫苗接种引发的广泛靶向刺突蛋白反应
Front Immunol. 2022 Feb 22;13:835830. doi: 10.3389/fimmu.2022.835830. eCollection 2022.
6
Humoral immune responses associated with control of SARS-CoV-2 breakthrough infections in a vaccinated US military population.体液免疫反应与接种疫苗的美国军人人群中对 SARS-CoV-2 突破感染的控制有关。
EBioMedicine. 2023 Aug;94:104683. doi: 10.1016/j.ebiom.2023.104683. Epub 2023 Jul 4.
7
Heterologous and homologous COVID-19 mRNA vaccination schemes for induction of basic immunity show similar immunogenicity regarding long-term spike-specific cellular immunity in healthcare workers.不同和同源的 COVID-19 mRNA 疫苗接种方案在诱导医护人员的长期刺突特异性细胞免疫方面显示出相似的免疫原性。
Vaccine. 2024 Aug 30;42(21):126132. doi: 10.1016/j.vaccine.2024.07.033. Epub 2024 Jul 20.
8
Hybrid immunity by two COVID-19 mRNA vaccinations and one breakthrough infection provides a robust and balanced cellular immune response as basic immunity against severe acute respiratory syndrome coronavirus 2.两剂 COVID-19 mRNA 疫苗和一次突破性感染产生的混合免疫为严重急性呼吸综合征冠状病毒 2 提供了强大而平衡的细胞免疫反应作为基础免疫。
J Med Virol. 2024 Jun;96(6):e29739. doi: 10.1002/jmv.29739.
9
Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial.两剂 BNT162b2 新冠疫苗接种后的免疫反应和奥地利蒂罗尔州 SARS-CoV-2 突破感染的风险:一项开放标签、观察性 4 期试验。
Lancet Microbe. 2023 Aug;4(8):e612-e621. doi: 10.1016/S2666-5247(23)00107-6. Epub 2023 Jun 21.
10
Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.单次免疫表达刺突蛋白和核衣壳蛋白的重组 ACAM2000 痘苗病毒可保护仓鼠免受 SARS-CoV-2 引起的临床疾病。
J Virol. 2022 May 11;96(9):e0038922. doi: 10.1128/jvi.00389-22. Epub 2022 Apr 12.

引用本文的文献

1
Phase 2/3 study evaluating safety, immunogenicity, and noninferiority of single booster dose of AVX/COVID-12 vaccine.评估单剂次加强剂量的AVX/COVID-12疫苗的安全性、免疫原性和非劣效性的2/3期研究。
Sci Adv. 2025 Jun 27;11(26):eadq2887. doi: 10.1126/sciadv.adq2887.
2
Robust mucosal SARS-CoV-2-specific T cells effectively combat COVID-19 and establish polyfunctional resident memory in patient lungs.强大的黏膜严重急性呼吸综合征冠状病毒2特异性T细胞可有效对抗2019冠状病毒病,并在患者肺部建立多功能组织驻留记忆细胞。
Nat Immunol. 2025 Mar;26(3):459-472. doi: 10.1038/s41590-024-02072-9. Epub 2025 Jan 28.
3
The Trajectory of Antibody Responses One Year Following SARS-CoV-2 Infection among Indigenous Individuals in the Southwest United States.

本文引用的文献

1
Nucleocapsid-specific T cell responses associate with control of SARS-CoV-2 in the upper airways before seroconversion.核衣壳特异性 T 细胞应答与 SARS-CoV-2 在血清转换前在上呼吸道的控制有关。
Nat Commun. 2023 May 24;14(1):2952. doi: 10.1038/s41467-023-38020-8.
2
CD8 T cells contribute to vaccine protection against SARS-CoV-2 in macaques.CD8 T 细胞有助于猕猴对抗 SARS-CoV-2 的疫苗保护。
Sci Immunol. 2022 Nov 18;7(77):eabq7647. doi: 10.1126/sciimmunol.abq7647. Epub 2022 Nov 11.
3
Clinical and Immunological Features of SARS-CoV-2 Breakthrough Infections in Vaccinated Individuals Requiring Hospitalization.
美国西南部原住民个体感染 SARS-CoV-2 一年后抗体反应的轨迹。
Viruses. 2024 Oct 5;16(10):1573. doi: 10.3390/v16101573.
4
Evolution of protective SARS-CoV-2-specific B and T cell responses upon vaccination and Omicron breakthrough infection.接种疫苗和奥密克戎突破性感染后,新冠病毒特异性B细胞和T细胞保护性免疫反应的演变
iScience. 2024 May 28;27(6):110138. doi: 10.1016/j.isci.2024.110138. eCollection 2024 Jun 21.
5
SARS-CoV-2 breakthrough infections enhance T cell response magnitude, breadth, and epitope repertoire.SARS-CoV-2 突破感染增强了 T 细胞反应的幅度、广度和表位库。
Cell Rep Med. 2024 Jun 18;5(6):101583. doi: 10.1016/j.xcrm.2024.101583. Epub 2024 May 22.
6
Overview of Nucleocapsid-Targeting Vaccines against COVID-19.针对新冠病毒的核衣壳靶向疫苗概述。
Vaccines (Basel). 2023 Dec 3;11(12):1810. doi: 10.3390/vaccines11121810.
7
The characterization of CD8 T-cell responses in COVID-19.新型冠状病毒肺炎患者 CD8 T 细胞应答特征。
Emerg Microbes Infect. 2024 Dec;13(1):2287118. doi: 10.1080/22221751.2023.2287118. Epub 2024 Jan 11.
8
The Importance of Measuring SARS-CoV-2-Specific T-Cell Responses in an Ongoing Pandemic.在持续的大流行中测量新冠病毒特异性T细胞反应的重要性。
Pathogens. 2023 Jun 22;12(7):862. doi: 10.3390/pathogens12070862.
9
Impact of Omicron Variant Infection on Assessment of Spike-Specific Immune Responses Using the EUROIMMUN Quan-T-Cell SARS-CoV-2 Assay and Roche Elecsys Anti-SARS-CoV-2-S.奥密克戎变异株感染对使用EUROIMMUN Quan-T-Cell SARS-CoV-2检测法和罗氏Elecsys抗SARS-CoV-2-S检测法评估刺突蛋白特异性免疫反应的影响
Diagnostics (Basel). 2023 Mar 8;13(6):1024. doi: 10.3390/diagnostics13061024.
接种疫苗后住院的 SARS-CoV-2 突破性感染的临床和免疫学特征。
J Clin Immunol. 2022 Oct;42(7):1379-1391. doi: 10.1007/s10875-022-01325-2. Epub 2022 Jul 9.
4
Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant.完全接种疫苗的个体在感染 SARS-CoV-2 德尔塔变异株后免疫应答的特征。
Sci Transl Med. 2022 Apr 20;14(641):eabn6150. doi: 10.1126/scitranslmed.abn6150.
5
The interplay of viral loads, clinical presentation, and serological responses in SARS-CoV-2 - Results from a prospective cohort of outpatient COVID-19 cases.病毒载量、临床表现和血清学反应在 SARS-CoV-2 中的相互作用 - 来自门诊 COVID-19 病例前瞻性队列的结果。
Virology. 2022 Apr;569:37-43. doi: 10.1016/j.virol.2022.02.002. Epub 2022 Feb 18.
6
Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8 T cell responses.非中和抗体依赖的 SARS-CoV-2 控制与鼻内疫苗诱导的 CD8 T 细胞反应相关。
Cell Rep Med. 2022 Jan 19;3(2):100520. doi: 10.1016/j.xcrm.2022.100520. eCollection 2022 Feb 15.
7
SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)突破性感染引发强效、广泛且持久的中和抗体反应。
Cell. 2022 Mar 3;185(5):872-880.e3. doi: 10.1016/j.cell.2022.01.011. Epub 2022 Jan 20.
8
Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection.SARS-CoV-2突破性感染后的抗体反应及变异株交叉中和作用
JAMA. 2022 Jan 11;327(2):179-181. doi: 10.1001/jama.2021.22898.
9
COVID-19 Breakthrough Infections and Transmission Risk: Real-World Data Analyses from Germany's Largest Public Health Department (Cologne).新冠病毒突破性感染与传播风险:来自德国最大公共卫生部门(科隆)的真实世界数据分析
Vaccines (Basel). 2021 Nov 2;9(11):1267. doi: 10.3390/vaccines9111267.
10
Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study.SARS-CoV-2 Delta 变异株疫苗突破感染的病毒学和血清学动力学:一项多中心队列研究。
Clin Microbiol Infect. 2022 Apr;28(4):612.e1-612.e7. doi: 10.1016/j.cmi.2021.11.010. Epub 2021 Nov 23.